Comparing Strategies for Magnetic Functionalization of Microbubbles
Source abstract
Abstract
The advancement of ultrasound-mediated therapy has stimulated the development of drug-loaded microbubble agents that can be targeted to a region of interest through an applied magnetic field prior to ultrasound activation. However, the need to incorporate therapeutic molecules while optimizing the responsiveness to both magnetic and acoustic fields and maintaining adequate stability poses a considerable challenge for microbubble synthesis. The aim of this study was to evaluate three different methods for incorporating iron oxide nanoparticles (IONPs) into phospholipid-coated microbubbles using (1) hydrophobic IONPs within an oil layer below the microbubble shell, (2) phospholipid-stabilized IONPs within the shell, or (3) hydrophilic IONPs noncovalently bound to the surface of the microbubble. All microbubbles exhibited similar acoustic response at both 1 and 7 MHz. The half-life of the microbubbles was more than doubled by the addition of IONPs by using both surface and phospholipid-mediated loading methods, provided the lipid used to coat the IONPs was the same as that constituting the microbubble shell. The highest loading of IONPs per microbubble was also achieved with the surface loading method, and these microbubbles were the most responsive to an applied magnetic field, showing a 3-fold increase in the number of retained microbubbles compared to other groups. For the purpose of drug delivery, surface loading of IONPs could restrict the attachment of hydrophilic drugs to the microbubble shell, but hydrophobic drugs could still be incorporated. In contrast, although the incorporation of phospholipid IONPs produced more weakly magnetic microbubbles, it would not interfere with hydrophilic drug loading on the surface of the microbubble.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging · Ultrasound and Cavitation Phenomena
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, U.K.
Funding
Engineering and Physical Sciences Research Council · Institution of Engineering and Technology
References (70)
Show source-provided references
1. 10.1016/s0735-1097(84)80424-610.1016/s0735-1097(84)80424-6 ↗
2. 10.1038/nrd141710.1038/nrd1417 ↗
3. 10.1146/annurev.bioeng.8.061505.09585210.1146/annurev.bioeng.8.061505.095852 ↗
4. 10.1161/circresaha.108.18380610.1161/circresaha.108.183806 ↗
5. 10.1016/j.ultrasmedbio.2008.10.01310.1016/j.ultrasmedbio.2008.10.013 ↗
6. 10.1016/j.ultrasmedbio.2009.06.109110.1016/j.ultrasmedbio.2009.06.1091 ↗
7. 10.1109/tuffc.2013.276710.1109/tuffc.2013.2767 ↗
8. 10.1039/b823051j10.1039/b823051j ↗
9. 10.2310/7290.2006.0001610.2310/7290.2006.00016 ↗
10. 10.1016/s0301-5629(99)00062-910.1016/s0301-5629(99)00062-9 ↗
11. 10.3109/02656736.2012.66863910.3109/02656736.2012.668639 ↗
12. 10.1088/1674-1056/22/10/10430110.1088/1674-1056/22/10/104301 ↗
13. 10.1088/0031-9155/53/21/01610.1088/0031-9155/53/21/016 ↗
14. 10.1016/j.biomaterials.2011.05.01910.1016/j.biomaterials.2011.05.019 ↗
15. 10.1021/bm300099f10.1021/bm300099f ↗
16. 10.1016/j.msec.2013.03.00110.1016/j.msec.2013.03.001 ↗
17. 10.1039/c3sm51560e10.1039/c3sm51560e ↗
18. 10.2217/nnm-2017-002710.2217/nnm-2017-0027 ↗
19. 10.1016/j.matlet.2011.10.01310.1016/j.matlet.2011.10.013 ↗
20. 10.1121/1.480494210.1121/1.4804942 ↗
21. 10.1039/c5sm00864f10.1039/c5sm00864f ↗
22. 10.1007/s12195-017-0504-910.1007/s12195-017-0504-9 ↗
23. 10.1021/la503929c10.1021/la503929c ↗
24. 10.1179/175889709x44650710.1179/175889709x446507 ↗
25. 10.1530/erp-15-001810.1530/erp-15-0018 ↗
26. 10.1016/j.colsurfb.2017.01.02210.1016/j.colsurfb.2017.01.022 ↗
27. 10.1016/j.ultrasmedbio.2008.11.01010.1016/j.ultrasmedbio.2008.11.010 ↗
28. Mulvana, H.; Eckersley, R. J.; Browning, R.; Hajnal, J. V.; Stride, E.; Barrack, T.; Tang, M.; Pankhurst, Q.; Wells, D. Enhanced Gene Transfection in Vivo Using Magnetic Localisation of Ultrasound Contrast Agents: Preliminary Results. 2010 IEEE International Ultrasonics Symposium, 2010; pp 670–673.10.1109/ULTSYM.2010.5935952 ↗
29. 10.1088/1361-6560/aa858f10.1088/1361-6560/aa858f ↗
30. 10.1002/adfm.20090238810.1002/adfm.200902388 ↗
31. 10.1016/j.nano.2012.03.00710.1016/j.nano.2012.03.007 ↗
32. 10.7150/thno.1619210.7150/thno.16192 ↗
33. 10.1007/s11095-011-0643-y10.1007/s11095-011-0643-y ↗
34. 10.1039/c3sm51690c10.1039/c3sm51690c ↗
35. 10.1364/ol.39.00373210.1364/ol.39.003732 ↗
36. 10.7150/thno.2078110.7150/thno.20781 ↗
37. 10.1143/jjap.39.323010.1143/jjap.39.3230 ↗
38. 10.1039/c4sm00318g10.1039/c4sm00318g ↗
39. 10.1038/am.2016.3710.1038/am.2016.37 ↗
40. 10.1097/00004424-199812000-0000710.1097/00004424-199812000-00007 ↗
41. 10.1016/j.ultrasmedbio.2006.03.01710.1016/j.ultrasmedbio.2006.03.017 ↗
42. 10.1016/j.ultrasmedbio.2016.08.00210.1016/j.ultrasmedbio.2016.08.002 ↗
43. FDA. Feraheme (ferumoxytol) Injection Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf (accessed May 9, 2018).
44. FDA. DEFINITY Injection Label, 2001; pp 1–18.
45. European Medicines Agency. Sonovue—Annex I Summary of Product Characteristics, 2007.
46. 10.1016/j.colsurfb.2004.03.00710.1016/j.colsurfb.2004.03.007 ↗
47. 10.1016/j.ultrasmedbio.2010.09.00410.1016/j.ultrasmedbio.2010.09.004 ↗
48. 10.1016/j.ultrasmedbio.2013.08.01810.1016/j.ultrasmedbio.2013.08.018 ↗
49. 10.1109/tuffc.2016.261399110.1109/tuffc.2016.2613991 ↗
50. 10.1016/j.ultrasmedbio.2015.07.02410.1016/j.ultrasmedbio.2015.07.024 ↗
51. 10.1016/j.biomaterials.2013.05.05310.1016/j.biomaterials.2013.05.053 ↗
52. 10.1021/la302674g10.1021/la302674g ↗
53. 10.1016/j.colsurfa.2018.05.00110.1016/j.colsurfa.2018.05.001 ↗
54. 10.1088/0031-9155/51/4/00310.1088/0031-9155/51/4/003 ↗
55. 10.1016/j.ultrasmedbio.2006.07.01610.1016/j.ultrasmedbio.2006.07.016 ↗
56. 10.1016/j.jconrel.2010.04.01010.1016/j.jconrel.2010.04.010 ↗
57. 10.1039/c2sm07437k10.1039/c2sm07437k ↗
58. Greger R. · 1996 · 186510.1007/978-3-642-60946-6 ↗
59. 10.1002/cmmi.41410.1002/cmmi.414 ↗
60. 10.1111/j.1540-8175.1999.tb00144.x10.1111/j.1540-8175.1999.tb00144.x ↗
61. 10.1007/s13346-017-0366-710.1007/s13346-017-0366-7 ↗
62. 10.1016/j.jconrel.2017.07.04010.1016/j.jconrel.2017.07.040 ↗
63. Tietze R. · 2014 · 1 · 59510.1142/9789814520652_0016 ↗
64. 10.1021/acs.chemmater.6b0390510.1021/acs.chemmater.6b03905 ↗
65. 10.3390/ijms16102441710.3390/ijms161024417 ↗
66. FDA. LUMASON/Sonovue Injection Label; https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203684s002lbl.pdf, accessed 11/20/2018.
67. 10.1016/s0304-3835(97)00318-210.1016/s0304-3835(97)00318-2 ↗
68. 10.1002/chem.20160192510.1002/chem.201601925 ↗
69. 10.1016/j.febslet.2014.02.04610.1016/j.febslet.2014.02.046 ↗
70. 10.1021/acsami.6b1293210.1021/acsami.6b12932 ↗